But in reality, some of those smaller value customers several years ago are now some of the biggest customers we have today. So I think we continue to support the overall market of 30,000 and we’ll penetrate it, as you’ve seen each quarter methodically and properly train these accounts on the differentiation Jeuveau introduced some of the unique cash pay advantages that we offer. And I think Jeuveau then gets into these practices and whether they’re existing practices that switch more of their patients to our brand or new practices that are attracting a younger generation to this performance beauty category. I think there’s many ways to grow this pie. So as we look out, we feel very good about the overall dynamics that there’s many ways to grow in this market, and I think we’re capitalizing on both.
We’re in approximately 40% of accounts, but we estimate we may be in roughly 60% of the dollar value of the toxin market. Of course, these are estimates, they’re rough estimates, but that gives you a gauge in terms of how we’re tracking.
Uy Ear: And for the second question, with respect to the filler, there’s a format at scale that allows for late-breaking use, it’s called to topics. So that will take place at the end of the day on the 17. So kind of in keeping with late-breaking news, you can expect to see the top line results and some select secondaries and then just a quick snippet of the safety profile and conclusion?
David Moatazedi: And at this time, we’re not prepared to provide more color on our commercialization efforts. I think we’ll provide that as we get closer into the launch date and after FDA approval.
Operator: Thank you. Our next question comes from the line of Doug Tsao with H.C. Wainwright. Please proceed with your question,.
Doug Tsao: Hi. Good afternoon and congrats on the progress. Maybe just on the broader market, I think Sandra sort of you highlighted your belief that the market continues to be healthy. It doesn’t seem that everyone is necessarily experiencing the same kind of growth that you are, and obviously, you’re at a different stage in some of the participants. But how would you characterize the competitive dynamics right now and given the fact that some players aren’t necessarily performing as well as you or as well as the broader market. Are they making any tactical changes?
David Moatazedi: Yes. So I think the comments that we made around the broader market, we feel very confident and we have a healthy market here. We had forecast this year would be roughly in this mid to high single-digit growth. The first quarter is confirmatory of what we expected to see. And frankly, that is the trajectory we see over the coming five years as we guide out to 2028. I don’t want to speak to one quarter on any competitor because I think in all fairness, there’s a lot more moving parts likely within any one company. So I’d rather not go there, except to say that, look, if I were looking at this category overall, I’d expect every toxin player in the space to deliver some level of growth this year because we have a healthy backdrop of the market.
I think our contribution to the growth and perhaps our over-indexing on growth that you’re seeing is a function of our positioning against this younger demographic. That is the catalyst and growth driver for this category and the way that our brand is positioned, the benefits that, that consumer receives and the practices received in order to go recruit more new consumers to their office are the catalysts that are driving our above index growth. And to the extent that, that leads to further share gains, that’s hard for us to estimate, but we believe it’s a function of where we’re positioned in the market. And we think it’s a sustainable differentiation that we can continue to build on to grow this category.
Doug Tsao: And David, maybe — and I hope this doesn’t get too granular. Can you sort of provide some perspective on how you think the different segments of the market might be growing and that would be like the millennials versus Gen X versus boomers to the extent that they’re still getting aesthetic procedures? How much variability across those segments do you see?
David Moatazedi: Yes. I’m expecting in the coming quarters will likely have a concrete data set that could answer that from a third-party, and I think that’s an important question, Doug. Unfortunately, we don’t have that in front of us aside from sharing with you that we continue to increase our mix towards millennials. And we believe the millennials are approaching the majority of users in the toxin market or they’re right near that tipping point. And I wouldn’t be surprised to see a data set that suggests that they’re already there. That backdrop is a very favorable one. I think for the whole category, frankly, because that’s what’s going to fuel this category over the next five years. But importantly, for us, given where we positioned the company when we launched about five years ago, we’re starting to see the benefits of that forward thinking positioning as a company.
Doug Tsao: Okay. Great. Thank you so much.
Operator: Thank you. Our next question comes from the line of Serge Belanger with Needham & Company. Please proceed with your question.
Serge Belanger: Hi. Good afternoon. Thanks for taking my questions. I think Sandro mentioned that Jeuveau growth in the first quarter was mostly driven by volumes. So I assume pricing was very stable. Just curious what your expectations are on the pricing front for this market as more competitors come in? And could it eventually kind of replicate what we’re seeing now in the European markets in terms of pricing levels. Thanks.
Sandra Beaver: Thanks for the question, Serge. Yes, that’s exactly how we frame the quarter, and it is the right inference that pricing has remained very stable. We’ve said in the past, and nothing has really changed despite continued movement in the market that we see nothing but strength in terms of upward mobility for us on price, right? So we could see modest increases. I’m not expecting to see meaningful decreases in the price. The U.S. market doesn’t behave like the European market. It’s not a race on price. It really is driven by the quality of the performance of the products first and foremost. And we tend to differentiate ourselves against the quality of Jeuveau, and that continues to give us that strength and our pricing position.
